Home / News / Advocacy

Advocacy

NIH Releases 2018 Funding Opportunities

NIH has reissued the CREATE Bio, Blueprint Neurotherapeutics and NeuroNEXT initiatives, along with other initiatives that focus on biomarker development and clinical trial readiness, to support therapy development efforts.

Giving Tuesday Campaign: Double Your Impact

Make a gift to MDF during our Giving Tuesday campaign and double the impact of your donation! Thanks to the generosity of the Haylon and Lord families, MDF will match all gifts made now through December 5th, up to the first $10,000 raised.

MDF Secures Compassionate Allowances Designation for CDM

After a year of outreach and education, MDF has successfully convinced the Social Security Administration (SSA) to list congenital myotonic dystrophy (CDM) in its Compassionate Allowances program, significantly easing the application and review process.

DM Voice of the Patient Report Submitted to the FDA

MDF held the first myotonic dystrophy (DM) Patient-Focused Drug Development (PFDD) meeting with key senior leaders from the Food and Drug Administration (FDA) as part of the 2016 MDF Annual Conference in September 2016.

Myotonic Dystrophy Foundation Statement Regarding: American Health Care Act

In March, Republican Members of the U.S. House of Representatives’ Committee on Ways and Means and the U.S. House Committee on Energy and Commerce introduced legislation, entitled the American Health Care Act (AHCA), that would repeal and/or replace major parts of the Affordable Care Act (ACA).

MDF Finished Year 10 with Flying Colors

2016 was a banner year for the Myotonic Dystrophy Foundation. We completed our 10th year driving Care and a Cure for people and families living with DM, wrapped up year 2 of a 3-year, $5M drug development acceleration effort and oversaw the largest expansion of our Care programming and resources ever. 

21st Century Cures Act Becomes Law

Thanks to the hard work and commitment of advocates from the MDF community and many others, critical legislation has moved forward that will accelerate the approval of new drugs and medical devices to treat and cure rare diseases like myotonic dystrophy.

MDF Staff Meets with NIAMS and NINDS

In November, Myotonic Dystrophy Foundation (MDF) staff met with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) senior leadership and program/policy staff to discuss research opportunities and federal support for myotonic dystrophy (DM). Discussions focused on two areas: the scientific workforce and biomarker and registration endpoint development.

MDF Honors Community Leadership Award Winners

Congratulations to our Community Leadership Award winners: Loraine Dressler, Carolyn Valek and Eric & Taylor Jensen! Click here to learn more about the amazing work they do for Care and a Cure.

DM PFDD Meeting - Bringing Your Voice to Therapy Development

MDF held the first myotonic dystrophy Patient-Focused Drug Development meeting with key senior leadership from the Food and Drug Administration (FDA) as part of the 2016 MDF Annual Conference. We designed the meeting to build on the work MDF has been conducting with the FDA to define and optimize the regulatory pathway for potential DM therapies. The meeting, the first Externally-Led PFDD meeting and the largest PFDD meeting held to date with over 200 attendees in the room and online, is helping change the way the FDA understands DM, the DM community and the approach to regulatory review for DM therapies. 

Partners

University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.